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ABSTRACT 22 
 23 
Cancer comprises a collection of highly proliferative and heterogeneous cells growing within 24 
an adaptive and evolving tumour microenvironment. Cancer survival rates have significantly 25 
improved following decades of cancer research. However, many experimental and 26 
preclinical studies do not translate to the bedside, reflecting the challenges of modelling the 27 
complexities and multicellular basis of human disease. Organoids are novel, complex, three-28 
dimensional ex vivo tissue cultures that are derived from embryonic stem cells, induced 29 
pluripotent stem cells or tissue resident progenitor cells, and represent a near-physiological 30 
model for studying cancer. Organoids develop by self-organisation and can accurately 31 
represent the diverse genetic, cellular and pathophysiological hallmarks of cancer. In 32 
addition, co-culture methods and the ability to genetically manipulate these organoids have 33 
widened their utility in cancer research. Organoids thus offer a new and exciting platform 34 
for studying cancer and directing personalised therapies. This review aims to highlight how 35 
organoids are shaping the future of cancer research. 36 
 37 
  38 
Background  39 
Cancer mortality rates have significantly declined by approximately 26% over the 40 
past two decades,1 a decrease that is attributable to early diagnosis and treatment of 41 
malignancy, evidence-based clinical pathways for surveillance and management of 42 
premalignant lesions, increased awareness of health-related behaviours such as smoking, 43 
and clinically-focused cancer research. In spite of this success, however, cancer is the most 44 
common cause of death in the UK, and is expected to continue to remain as such, with 45 
212,546 cancer deaths predicted for 2035.2,3 46 
As we continue to make progress towards a ‘cure for cancer’, it is apparent that data 47 
from many experimental and preclinical studies do not to translate from bench to 48 
bedside,4,5 an observation that is thought to reflect the challenges of modelling the 49 
complexities and multicellular basis of human disease.6 Despite these challenges, several 50 
pivotal systems such as two-dimensional (2D) cell cultures, explants, organ-on-a-chip 51 
systems and animal models will continue to be essential to understand the biology of 52 
cancer. Nevertheless, novel and innovative model systems can improve the translational 53 
success of preclinical studies, and the methodology for tumour-derived organoid cultures 54 
has consequently emerged (Figure 1). Organoids are complex, 3D, ex vivo tissue cultures 55 
that are derived from embryonic stem cells, induced pluripotent stem cells or tissue-56 
resident progenitor cells. They possess spatially restricted lineage commitment and higher-57 
order self-assembly, which makes them attractive near-physiological models.7 This review 58 
will firstly discuss the advantages and disadvantages of the experimental model systems 59 
that are currently used in cancer research, leading to a review of tumour-derived organoid 60 
model systems, including applications in cancer research, highlighting advantages, including 61 
potential utility in personalised medicine, limitations and future perspectives.  62 
 63 
Current experimental model systems in cancer research 64 
Several experimental model systems are currently applied to cancer research. 65 
Although a comprehensive overview of current laboratory models for cancer research is 66 
beyond the scope of this review, and is available elsewhere,8-10 the advantages and 67 
disadvantages are outlined in Figure 2 and discussed below.  68 
 69 
2D cell culture, tissue slices and tissue explant culture  70 
2D cell cultures — either primary cell cultures (grown directly from patient or animal 71 
tumours) or well-characterised immortalised cell lines — have been extensively used to 72 
study cancer. Although primary cell lines have a limited life-span and are slow-growing, they 73 
are advantageous because they maintain some donor-cell characteristics and can be linked 74 
to clinicopathological data. By contrast, artificial manipulation or natural genetic mutations 75 
confer on immortalised cell lines the ability to proliferate indefinitely, making them a more 76 
convenient and well-established preclinical model, but rendering them less representative 77 
of the original tumour; furthermore, serial passages induce genotypic and phenotypic 78 
changes that might confound experimental results.11 Irrespective of their origin, 2D cell 79 
cultures cannot replicate intra-tumour cellular heterogenicity, lack the complex extracellular 80 
microenvironment, have forced apicobasal polarity and are grown as a monolayer with 81 
unnatural suspension and adherence forces. Although co-cultures and transwell assays can 82 
address some of these issues, the biological translation of 2D cell culture models can be 83 
limited. 84 
Tissue slices and organ cultures derived from tissue explants provide the 85 
architecture, morphology and cellular composition that 2D cell cultures lack. However, 86 
these models have a short lifespan (most tissues are viable for 24 hours; liver can be viable 87 
up to 96 hours) and are expensive and difficult to maintain.12 88 
 89 
Organ-on-a-chip technology 90 
Organ-on-a-chip technology refers to a multi-channel microfluidic perfusion culture 91 
system, made from glass, plastic or a flexible polymer, that is lined with living human cells.13 92 
This system allows more accurate modelling of organ system physiology: for example, it 93 
facilitates the establishment of tissue–tissue interfaces, has separate vascular, extracellular 94 
and parenchymal compartments, and allows for physiologically-representative co-culture 95 
with microbes and immune cells.14 In cancer research this technology has been used to 96 
study interactions between tumour cells and the extracellular milieu, cancer-associated 97 
epithelial–mesenchymal transition, angiogenesis, tumour invasion, cell migration and 98 
metastasis. Despite this impressive résumé, this model does have disadvantages: for 99 
example, organ-on-a-chip platforms commonly use cell lines and there is often significant 100 
variation and inconsistency between different chips, making experimental replication 101 
difficult. 102 
 103 
Animal models 104 
Preclinical animal models continue to be a key aspect of cancer research and these 105 
have been reviewed elsewhere.15-20 Tumour growth in vivo can be induced by chemicals 106 
(e.g. azoxymethane mouse model of colorectal cancer), viruses (e.g. Friend-virus-induced 107 
erythroleukaemia in mice) or radiation (e.g. UV radiation-induced melanoma in mice). 108 
Genetically engineered animals are popular because tumours can be induced to develop in 109 
transgenic mice (e.g. mice lacking the adenomatous polyposis coli [APC] gene are used to 110 
study the adenoma–carcinoma sequence in colorectal cancer) or knockout mice (e.g. the 111 
BRCA1 conditional knockout mouse model using Cre/loxP recombination is used to study 112 
breast cancer) and key genes can be conditionally manipulated.15,21 113 
Animal models are fundamental for translational cancer research — both for 114 
biological studies of pathogenesis and functional drug studies — and continue to be one of 115 
the cornerstone experimental approaches in the cancer research field. However, they do 116 
have limitations.16,21 Animal models are expensive, require extensive resources, and the 117 
data from many promising preclinical animal studies are often not validated in human 118 
models, or do not proceed in drug development towards clinical application,21,22 reflecting 119 
the different genetic, cellular and immunological characteristics in animals compared with 120 
humans. Steps taken to overcome these issues include transplanting human cancer tissue or 121 
cell lines into humanised rodents.23,24 These xenografts can be orthotopic (transplanted into 122 
the anatomical location from where the tumour was derived) or heterotopic (transplanted 123 
elsewhere e.g. subcutaneously or intra-peritoneally).  124 
 125 
3D cell models: tumour-derived organoid cultures  126 
A critical player in organoid cultures is the stem cell, a self-renewing cell that can 127 
give rise to many different cell types within a tissue. Stem cells display unique markers such 128 
as leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) in the intestine. In 129 
2009, Sato and colleagues reported that single-cell-sorted Lgr5+ stem cells located at the 130 
bottom of intestinal crypts can initiate crypt-villus organoids when embedded in Matrigel (a 131 
gelatinous protein matrix that provides the structural architecture to support 3D growth), 132 
and that these intestinal organoids contained differentiated cell types that are present in 133 
the original tissue.7 134 
It is important to distinguish organoids from spheroids: both are cultured in a 3D 135 
format, but spheroids are simpler, homogenous, 3D structures that lack the multiple cell 136 
types seen in organoids. Spheroids typically represent free-floating cell aggregates with no 137 
matrix component — they usually depend on cell–cell adhesion for viability. Spheroids can 138 
be generated from immortalised cell lines, primary cells or fragments of tissue and, as such, 139 
their viability is limited as they do not contain a progenitor phenotype. Spheroids develop a 140 
necrotic core as they grow in size, and possess no or limited tissue structure and a less 141 
representative tissue architecture (e.g. no central lumen).25 Hence, although spheroid 142 
culture is a useful 3D culture methodology, offering a bridge between traditional 2D culture 143 
and costly in vivo animal studies, organoid-based 3D culture methodology offers several 144 
advantages to spheroids owing to enhanced architectural and physiological functions. 145 
 146 
Establishing and maintaining organoid cultures  147 
The epithelial compartments of many tissues, including normal, pre-malignant 148 
tissues and tumours, have been modelled using organoids.26 Although the tissue for 149 
organoid culture is most commonly derived from surgical resection specimens,27,28 organoid 150 
cultures have been successfully established from other tissue sources, for example, 151 
endoscopic biopsy from Barrett’s oesophagus,27 needle biopsy for hepatocellular 152 
carcinoma,29 endoscopic ultrasound-scan-guided fine-needle biopsy for pancreatic ductal 153 
adenocarcinoma30 and ascitic fluid for both pancreatic and ovarian cancers.25,31 Successful 154 
tumour organoid cultures can therefore be generated from a small amount of biological 155 
material and from cancers that are difficult to access in the clinical setting. Previously, the 156 
interval between specimen collection and successful establishment of organoid culture has 157 
been dictated by the viability of fresh samples, which has limited the time, location and 158 
demographic from which a patient sample can be taken, but Tsai and colleagues published a 159 
robust method in 2018 to cryopreserve fresh human biopsy tissue and later thaw the 160 
specimen to generate gastrointestinal organoid cultures, thus overcoming this limitation.32 161 
The diverse methods for tissue acquisition and the ability to cryopreserve specimens 162 
highlight the functional utility of organoid culture across a variety of cancer types and 163 
clinical situations.  164 
Organoid cultures have been well-characterised in the literature and this has 165 
provided a robust evidence base to validate the use of these models. For example, 166 
oesophageal adenocarcinoma organoids derived from oesophagectomy tissue specimens 167 
recapitulate the diverse genomic and transcriptomic landscape of the primary tumour,33,34 168 
and histological assessment of these organoids demonstrated that the original tumour 169 
architecture and protein expression profile was maintained.33 This faithful representation 170 
has been reported across a variety of other tumour types including, but not limited to, lung, 171 
ovarian, uterine, colorectal, bladder, liver, breast and biliary tract cancers.29,34-38 There is 172 
also evidence that epigenetic signatures in organoids appear to be reflective of those found 173 
in the primary lesion, indicating the biology of the tumour is broadly represented.39 174 
Once organoid cultures have been established, they require a complex and 175 
individualised combination of growth factors for survival and maintenance. It is essential to 176 
use optimised media formulations to ensure that experiments are reliable and reproducible. 177 
Organoid cultures from different tissues will have unique media requirements. Subtle 178 
changes to these cocktails can have marked consequences — for example, normal colonic 179 
organoids will outcompete colonic cancer organoids when cultured in media optimised for 180 
normal colonic organoids, potentially owing to apoptosis resulting from genomic instability 181 
in the tumour organoids.35 However, the sensitivity of organoids to growth factors can be 182 
exploited to establish many tumour organoid cultures. For example, normal colonic 183 
organoids require the ligand Wnt3a for survival whereas the majority of colonic cancer cells 184 
demonstrate hyperactivation of the Wnt/β-catenin pathway independent of Wnt3a.40 185 
Therefore, the selective removal of Wnt from organoid media prevents normal colonic 186 
organoids from outcompeting colonic cancer organoids.35 Not all colonic tumour cells 187 
display aberrant Wnt signalling though, and therefore it is important to explore the 188 
implications of selecting tumour cells by their requirement(s) for specific factors.41,42 In 189 
future, it might be informative to use growth factor requirements to characterise, rather 190 
than select, tumour organoids. Nonetheless, it is important to remember that organoid 191 
function can be influenced by altering their media conditions, and it is therefore important 192 
to characterise organoid cultures before experimentation. 193 
Long-term organoid culture is possible, with most groups reporting successful 194 
culture up to 6 months,27,33 and some groups reporting success beyond 1 year.43 Patient- 195 
and disease-specific characteristics are retained well over several passages.43 There is 196 
evidence that mutations do accumulate over time33 although this is perhaps unsurprising, 197 
given the known evolution of cancer in vivo,44,45 and this is consistent with tumour evolution 198 
in vitro.36 Tumour organoids also possess distinct organoid signatures that reflect real-life 199 
inter-patient variability.46 However, such inter-patient variability increases the sample size 200 
requirements for robust power-calculation-based experiments, which can be expensive. 201 
Ultimately, though, the expense must be weighed against the ability of this model to more 202 
accurately represent human disease.  203 
 204 
Advantages and limitations of organoid models in cancer research 205 
Our ability to manipulate tumour organoids improves further the utility of this culture 206 
system in cancer research. Several experimental approaches can be used to reveal novel 207 
insight into cancer pathogenesis (Figure 3). 208 
 209 
Tumour organoids enhance the utility of 2D cell culture  210 
As discussed above, 2D cell cultures constitute a key experimental platform in 211 
laboratory research — a myriad of validated experiments can be performed using these 212 
simple and inexpensive cultures. Consequently, the ability to establish 2D monolayers from 213 
epithelial-derived organoids allows functional experiments to be carried out, such as wound 214 
healing and transepithelial electrical resistance assays to measure functional permeability, 215 
while maintaining the unique characteristics of ex vivo organoid cultures, such as molecular 216 
identity to the original tissue and presence of a number of different epithelial cell types, 217 
such as parietal, chief and mucous neck surface mucosal cells from the stomach (Figure 4).47 218 
High-throughput microscopy can be performed in 2D-organoid-derived monolayer cultures, 219 
which would be difficult to perform in the 3D equivalent.  220 
However, given the increased complexity of organoid models, there are some 221 
considerations for applying traditional 2D-based assays to 3D cultures. For example, 222 
organoid-derived monolayers cannot be easily passaged or propagated in 2D; instead they 223 
achieve a homoeostatic state with balanced proliferation, differentiation and apoptosis.48 In 224 
addition, the efficiency of gene-silencing using small interfering (si)RNA is significantly 225 
reduced in the presence of serum in 2D cultures, whereas serum improves knockdown 226 
efficacy in organoid cultures by promoting the internalisation of siRNA.49 227 
 228 
Genome editing improves the functional utility of organoids for cancer research 229 
 Genome editing has been used to improve the use of organoid models and, as such, 230 
normal/non-cancerous organoid cultures can be genetically manipulated to undergo 231 
malignant transformation. The prokaryotic clustered regulatory interspaced short 232 
palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system has revolutionised 233 
how we approach genome editing in the laboratory, allowing precise and consistent in vitro 234 
genome editing.50 As an example, in human cerebral organoids, CRISPR/Cas9 technology has 235 
been used to facilitate the expression of an oncogenic HRasG12V construct by homologous 236 
recombination into the TP53 locus, thereby simultaneously disrupting this tumour 237 
suppressor locus.51 This approach enables putative initiating genetic mutations to be 238 
recreated and the natural history of tumour initiation of human gliomas to be followed. 239 
CRISPR/Cas9 has also been used to study the origin of mutational signatures in cancer by 240 
the selective deletion of critical DNA repair genes.52 241 
 By inserting an inducible histone 2B-green fluorescent protein (GFP) reporter into 242 
patient-derived organoid cells, CRISPR/Cas9 technology has been used to track quiescent 243 
versus proliferative cells during glioblastoma recurrence.53 Due to the ability of organoids to 244 
maintain tumour cell heterogenicity, this genetic manipulation allowed researchers to 245 
compare quiescent cells from glioblastoma tumours with their proliferative counterparts, 246 
which has revealed novel insight into the pathophysiology of glioblastoma. Indeed, 247 
quiescent cells were reported to differentially express genes involved in cell-cycle control, 248 
metabolic adaptation, interaction with the extracellular matrix, and mesenchymal 249 
transition, and showed higher resistance to therapy compared with proliferative cells. Both 250 
hypoxia and transforming growth factor-β were identified as potential niche factors that 251 
promoted quiescence. This use of organoid technology has therefore laid the foundations 252 
for developing new therapeutic strategies for glioblastoma by uncovering novel mechanisms 253 
of recurrence for this tumour.53 254 
 To model the well-defined progression from adenoma to carcinoma that occurs 255 
during colorectal carcinogenesis, CRISPR/Cas9 has been used to genetically engineer 256 
sequential mutations associated with stem-cell niche regulation, senescence and DNA 257 
mismatch repair in colonic organoids from mice to mirror the molecular pathogenesis of 258 
serrated colorectal cancer.54 Following genetic manipulation, the resulting requirement for 259 
growth factors in the stem-cell niche was exploited to select for mutant organoids, and 260 
subsequent colonoscopy-guided orthotopic injection of organoids into mice was performed 261 
to investigate the contribution of specific mutations to carcinogenesis. The resultant 262 
tumours arising in vivo were reflective of human disease. This study demonstrates how 263 
genetically modified organoids can be used to create novel orthotopic models of cancer. 264 
Genome editing in organoids has also revealed novel insight into the 265 
pathophysiology of previously hard-to-model diseases. Barrett’s oesophagus describes distal 266 
oesophageal columnar metaplasia with malignant potential. The disease is difficult to study 267 
because available cell lines and animal models are poorly representative of the underlying 268 
biology – cell lines lack the phenotypic diversity seen in the oesophageal submucosal glands 269 
and mouse models do not accurately model neoplastic progression.55,56 Through the use of 270 
CRISPR/Cas9 technology, patient biopsy-derived Barrett’s organoids that lack APC have been 271 
generated and used to demonstrate a fundamental role of aberrant Wnt/β-catenin 272 
signalling in the neoplastic progression of Barrett’s-associated oesophagus.57 273 
Alternative, less costly and time-consuming methods of genomic manipulation have 274 
also been reported in the context of gene editing. Such examples include lentiviral 275 
transduction of prostate epithelial organoids to demonstrate that genetic alterations that 276 
are commonly found in human prostate cancer can be modelled in human organoid 277 
culture,58 and magnetic nanoparticle viral transduction of gastrointestinal organoids for 278 
further study in in vitro assays or in vivo functional analyses in mice.59 279 
 280 
Organoids recreate the structural organisation of their origin tissue  281 
 Organoids can also recapitulate the spatial arrangement of their tissue of origin. 282 
When non-neoplastic bronchial mucosa failed to maintain their organoid ‘status’ during 283 
subculturing, Kim and colleagues added supplements known to promote lung development, 284 
which resulted in formation of bronchial cells; by passage four, budding tubule-like 285 
organoids had emerged.60 Haematoxylin and eosin staining demonstrated that the 286 
organoids had pseudostratified epithelium, comprising basal cells and luminal cells, that 287 
resembled normal bronchial mucosa. Interestingly, the non-neoplastic bronchial organoids 288 
had motile cilia found in large bundles whereas lung cancer organoids had one single 289 
primary cilium per cell, indicating that, under the correct conditions, organoids can 290 
represent the structural organisation of their tissue of origin. In creating an organoid 291 
biobank from non-neoplastic and different subtypes of lung cancer tissue, the architectural, 292 
protein expression profile and molecular profiling was maintained from the tissue of origin.  293 
Recreating structural morphology is especially important for cancers that arise from 294 
tissues with high structural organisation, such as the colon and rectum. Colorectal organoids 295 
self-organise to maintain apicobasal polarity with a hollow central lumen.61 This is a unique 296 
feature of organoid culture that reflects human anatomy and physiology, and it allows 297 
straightforward access to the basolateral surface via the culture media. Access to the 298 
luminal surface, however, is more difficult and, given the importance of antigens, 299 
microbiota and cell signalling receptors at the luminal surface of the epithelial barrier in 300 
colorectal carcinogenesis, there has been a focussed effort to improve luminal accessibility 301 
in organoid models. Breakdown of the epithelial barrier, with the consequent translocation 302 
of bacteria and luminal antigens through the colonic mucosa, is believed to be an important 303 
initiating event in colorectal carcinogenesis,62 and a protocol for the microinjection of 304 
fluorescently-labelled dextran into patient-derived human intestinal organoids establishes a 305 
platform to study epithelial barrier dynamics in vitro.61 Breakdown of the epithelial barrier 306 
will result in increased permeability and translocation of fluorescently-labelled dextran from 307 
the organoid lumen to the extracellular space. In addition to barrier integrity, the 308 
contribution of host–microbiota interactions to colorectal carcinogenesis can be studied by 309 
microinjection of live bacteria into the centre of colorectal organoids.63 Microinjection can 310 
be arduous and time consuming in the case of a large number of organoids. High-311 
throughput microinjection of organoids is a solution to this problem and can be achieved in 312 
the laboratory with semi-automated microinjection, microfabricated cell culture devices and 313 
computer vision systems (CVis).64 This technique could be applied to organoid cultures 314 
derived from various tumours, and could facilitate the injection not only of bacteria, but 315 
also of chemical compounds, biological molecules, siRNA and other microorganisms. 316 
One of the hallmarks of cancer is a loss of tissue organisation. Developments in 317 
microfabrication technology now enable organoids to be integrated into an extracellular 318 
matrix that contains specific biomolecules. For example, one study using normal breast 319 
organoid cultures created a defined chemoattractant gradient, using growth factors such as 320 
epidermal growth factor, to direct the formation of epithelial branches.65 This approach 321 
allows tissue-specific spatial and chemical factors to be considered in organoid cultures and, 322 
furthermore, can be adapted for use in cancer research — for example, to provide insight 323 
into factors that contribute to the loss of breast tissue organisation during carcinogenesis.  324 
 325 
The tumour microenvironment can be represented in organoid cultures using co-culture  326 
Many laboratory findings fail to translate to the clinic because cell cultures do not 327 
accurately recapitulate cell behaviour and function within the wider tumour 328 
microenvironment, which includes the extracellular matrix, blood vessels, signalling 329 
components and other cell types. Consequently, organoids offer a biologically relevant 330 
platform to improve translatability. Co-cultures are not a new concept in the laboratory as 331 
they are often used to study interactions between epithelial cells and other important cell 332 
populations, such as lymphocytes, neurones and blood vessels. The successful co-culture of 333 
epithelial cancer organoids with immune cells has revealed important insights into the 334 
pathogenesis of many cancers, and the ability to genetically manipulate such organoids with 335 
or without immune cells provides a specific and relevant model for studying 336 
carcinogenesis.66-68 Co-culture of mouse tumour organoids with adipocytes has provided 337 
novel insight into colon cancer. For example, Wen and colleagues demonstrate that 338 
adipocytes promote the proliferation and dedifferentiation (detected by increased Lgr5 and 339 
CD44, and decreased mucin 2 and sucrase-isomaltase mRNA levels) of colon cancer 340 
organoids.69 The authors further suggest that adipocytes function as a metabolic regulator 341 
and energy provider to promote the growth of colon cancer cells, which offers a potential 342 
mechanism to help explain the relationship between obesity and colorectal cancer.  343 
The extracellular matrix is not a passive bystander in cancer biology; however, the 344 
biological consequences of this are often not explored or adjusted for in traditional 345 
laboratory experiments.70 Co-culture experiments can overcome this. For example, 346 
established pancreatic ductal adenocarcinoma organoids normally develop ductal and 347 
basement membrane structures, but this organisation is lost following co-culture with 348 
pancreatic stellate cells in a collagen matrix, coincident with basement membrane 349 
destruction and increased invasion into the collagen matrix.71 Furthermore, co-culturing 350 
pancreatic cancer organoids with both stromal and immune cells leads to the activation of 351 
myofibroblast-like cancer-associated fibroblasts, an observation that was not apparent in 2D 352 
culture models.25 A model system that allows interaction between cancer cells, stromal cells 353 
and immune cells is therefore important for studying the pathogenesis of cancer. 354 
As well as making organoid cultures more representative of the in vivo scenario, co-355 
culture can improve the differentiation yield. For example, co-culture of human induced 356 
pluripotent stem cells with human adipose microvascular endothelial cells leads to an 357 
increased yield of hepatocyte-like clusters and the generation of hepatocyte-like organoids 358 
that resemble mature tissue rather than cell cultures.72 There is also evidence that adding 359 
primary prostate stromal cells to 3D cultures of human prostate epithelial cells increases the 360 
formation of prostate organoids and non-random architectural organisation in the form of 361 
branching.73 362 
Techniques to improve organoid cultures continue to emerge, such as the use of 363 
self-generating hydrogels comprising extracellular matrix derived from human tissue instead 364 
of Matrigel. For example, Mollica et al.74 describe a method for generating extracts of 365 
mammary extracellular matrix that can spontaneously gel to form hydrogels. Importantly, 366 
these hydrogels retain biological signalling responses that are different between cancer and 367 
normal epithelial organoid cultures.74 368 
Air–liquid-interface systems, in which the basal surface of stem cells is in contact 369 
with the media and the apical surface is exposed to the air, have also attracted interest. This 370 
set-up can more accurately reflect the conditions of the tumour microenvironment in 371 
certain cancers such as the luminal surface of colorectal cancer.75 Usui et al75,76. successfully 372 
developed air–liquid interface organoid models from normal and tumour colorectal tissues 373 
of human patients and were able to demonstrate the presence of epithelial, goblet and 374 
fibroblast cells in normal colonic tissue, and epithelial, goblet, myofibroblast and cancer 375 
stem cells in colorectal cancer tissue, as well as to show that colorectal tumour organoids 376 
were more resistant to chemotherapeutic agents than colorectal cancer cell lines. Similarly, 377 
when investigating the effect of resistance to gemcitabine treatment, co-culture of 378 
pancreatic ductal adenocarcinoma organoids with cancer-associated fibroblasts resulted in 379 
an increased IC50 when compared with organoids cultured alone,25 indicating that organoid 380 
co-culture models can also offer novel insights into treatment responses. Ensuring a 381 
representative tissue microenvironment is therefore an important consideration for 382 
organoid culture in cancer research. 383 
 384 
Tumour organoids can enhance xenograft models 385 
 Patient-derived xenografts involve the implantation of human tissue or cells into 386 
humanised or immunodeficient rodents. This approach has provided invaluable insight into 387 
cancer invasion and metastasis; however, it can be improved further by the transplantation 388 
of organoids.77 Orthotopic transplantation is important to consider because subcutaneous 389 
xenografts often do not accurately recapitulate cancer invasion or metastasis.78 Orthotopic 390 
models of colorectal cancer have been developed from organoids and seen to produce 391 
uniform tumours that grow and metastasise reliably, dependent on the metastatic potential 392 
of the cancer cells.78 One key example is the immunocompetent mouse model of colorectal 393 
cancer that recapitulates the well-defined human adenoma–carcinoma–metastasis 394 
sequence following orthotopic transplantation of colonic organoids.79 This approach can be 395 
applied to native or genetically modified human or mouse organoids: progression to 396 
adenocarcinoma occurs over 6 weeks and spontaneous metastasis takes more than 20 397 
weeks. Similar protocols use colonoscopy-guided mucosal injection and transplantation of 398 
organoids into the caecal mucosa of the mouse colon.80,81 399 
 A similar case exists in rectal cancer, for which there is a lack of anatomically-400 
relevant endoluminal rectal cancer mouse models. Ganesh and colleagues transplanted 401 
patient-derived rectal cancer organoids into mice,82 resulting in the generation of an 402 
invasive rectal carcinoma that metastasises to the liver and lung, as expected. Furthermore, 403 
the engrafted tumours display heterogenous responses to chemotherapy, as also expected 404 
from clinical data.  405 
Orthotopic transplantation can also take place after phenotypic and/or genotypic 406 
characterisation and/or manipulation of the tumour. For example, CRISPR/Cas9 technology 407 
can be used to investigate the contribution of driver mutations in colorectal cancer.83 Such 408 
an approach could be used to generate the entire spectrum of cancer genotypes involved in 409 
carcinogenesis and metastasis,84 creating a biological library that can be used to investigate 410 
downstream phenotype changes, as has been reported.85,86 The insertion of a GFP tag by 411 
lentiviral transduction facilitates the straightforward detection of metastatic dissemination 412 
in such models.87 413 
Cancers that develop from an orthotopically transplanted breast cancer organoid in 414 
mouse models not only reflect the morphology of the tumour of origin but also the drug 415 
sensitivities, thereby rendering the ability to genetically modify such tumour-derived 416 
organoids invaluable in the study of drug resistance.88 Orthotopic transplantation 417 
overcomes many problems associated with other mouse models of colorectal cancer such 418 
as a high tumour burden and tumours arising in the small intestine rather than colorectum; 419 
as such, the use of organoids compared with cell culture clearly improves the translational 420 
ability of orthotopic transplant models. 421 
 422 
Future perspectives 423 
Tumour organoids can help replace, reduce and refine the use of animals in cancer 424 
research 425 
Replacing, reducing and refining (3Rs) the use of animals in research is an 426 
international priority, and patient-derived organoid cultures represent an exciting platform 427 
to facilitate this principle. There are still limitations such as inability to mirror systems-level 428 
interactions, multi-tissue interactions, multi-directional immune system interactions, and 429 
explorations of drug pharmacokinetics and pharmacodynamics. However, these alternative 430 
organoid-based methods are evolving to study primary tumours ex vivo, and are adapting in 431 
complexity to overcome some of these limitations. As an example, metastasis adds a whole 432 
new dimension and this process is difficult to study without the use of animal models. As 433 
discussed above, to overcome this, organ-on-a-chip technology constitutes an excellent 434 
animal-free model system for studying cancer metastasis, and can be improved by using 435 
organoid cultures. Aleman and Skardai have described a novel metastasis-on-a-chip system 436 
in which colorectal cancer cells within a cancer organoid reside in a single microfluidic 437 
chamber that is connected to downstream chambers containing liver, lung and endothelial 438 
constructs in order to assess the metastatic preference of colorectal cancer cells.89 Other 439 
examples include the development of breast cancer associated bone metastasis model90 440 
and a multi-organ chip based model of lung metastases with cell compartments 441 
representing bone, liver and brain.91 Organoids can therefore improve current disease 442 
models while helping to meet the international agenda outlined by the 3Rs.  443 
Matrigel, which is currently widely used in the synthesis of organoids, is a basement 444 
membrane matrix with biological activity derived from Engelbreth-Holm-Swarm murine 445 
sarcomas.92 Animal-free alternatives such as hydrogels made from alginates do exist and 446 
have been used in novel model systems of the tissue microenvironment, such as a 3D 447 
bioprinted multicellular construct of breast tissue containing breast cancer cells and 448 
adipocytes,93 or utilising hyaluronic acid and collagen in a novel immersion bioprinting 449 
technique to allow organoid culture in 96 well plates for high-throughput drug screening, 450 
validated with patient-derived glioblastoma and sarcoma organoids.94 451 
 452 
Could tumour organoids inform patient management?  453 
Organoids could be a future tool to facilitate decisions regarding patient 454 
management. As an example, patient-derived tumour organoids could help determine 455 
whether a particular patient will be sensitive or resistant to specific treatments for many 456 
cancer types in a personalised medicine approach.95-98 This knowledge could be especially 457 
useful when there are a lack of robust data from large randomised control trials, which is 458 
often the case for rare and metastatic cancers. For example, this approach has been 459 
explored using organoids from appendiceal,99 neuroendocrine prostate100 and sarcoma 460 
cancers94 to test the efficacy of various chemotherapeutic agents. Researchers in the 461 
Netherlands have also established colorectal cancer organoids from ascitic fluid and 462 
peritoneal metastasis and used them to assess sensitivity to chemotherapy agents in an in 463 
vitro hyperthermic intraperitoneal chemotherapy model.101 Consistent with variable clinical 464 
outcomes following hyperthermic intraperitoneal chemotherapy, the authors reported 465 
inter-patient variability in the response to commonly used chemotherapeutics, suggesting 466 
that organoids could potentially allow treatment regimens to be individualised to improve 467 
prognosis and reduce rates of recurrence.  468 
In addition to providing insight into individualised treatment responses, organoids 469 
could also help inform on drug toxicity.102,103 For example, rimonabant, a cannabinoid 470 
receptor 1 antagonist previously used in the management of obesity, which inactivates Wnt 471 
signalling and might therefore modulate cancer stemness in colorectal cancer, was shown to 472 
be selectively toxic towards colorectal cancer organoids but not healthy colonic cells, 473 
highlighting the potential use of rimonabant as a candidate for the treatment of colorectal 474 
cancer.104 The use of organoids for assessing response and toxicity to therapy is not 475 
restricted to chemical compounds, however, patient-derived rectal cancer organoids 476 
irradiated ex vivo were seen to display heterogenous sensitivities that correlate with the 477 
patient’s clinical response to radiotherapy.82 Furthermore, Nagle and colleagues used 478 
organoids to demonstrate that proton irradiation carried out in a magnetic field did not 479 
impact biological responses.105 480 
In addition to helping to select the correct therapy for patients, organoid models 481 
could also prevent cancer patients from receiving ineffective treatments. For example, in 482 
metastatic colorectal cancer, Ooft and colleagues demonstrated the use of patient-derived 483 
organoids in preventing patients from receiving ineffective irinotecan-based chemotherapy; 484 
interestingly, however, these patient-derived organoids were unable to predict the outcome 485 
for treatment with 5-fluorouracil plus oxaliplatin.106 486 
This potential approach to personalised medicine has limitations. There can be a low 487 
success rate of generating some organoid cultures, probably dependent on tissue type. For 488 
example, Li and colleagues report an efficiency rate of 31% for generating oesophageal 489 
adenocarcinoma organoids.33 Success rates could be improved by employing tissue quality 490 
evaluation protocols before culturing; this approach entails preparing and histologically 491 
examining an aliquot of cell suspension to select for epithelial cell prominent samples 492 
following tissue dissociation.60 493 
 Patient-derived organoid culture could be useful in the study of chemotherapy 494 
resistance. When a patient becomes resistant to therapy it might be possible to select for 495 
resistant cancer cells in culture by manipulating niche factor requirements, thereby 496 
facilitating screening for drugs that are effective against the resistant cells.107 High-497 
throughput sequencing of organoid cultures is difficult given that these cells are not likely to 498 
proliferate fast enough to generate the cells necessary for a very large screen. However, a 499 
bespoke, clinically relevant, drug screen could be performed on the resistant organoid 500 
culture to identify effective chemotherapy agents, and this approach appears more feasible 501 
at present. In addition, new methods to overcome this issue for high-throughput 502 
applications are emerging including the use of bioprinting with alternative support matrix 503 
combinations to allow organoid culture in small well culture plates, for example 96 or 384 504 
well plates.94 505 
Individualised cancer therapy based on ex vivo experiments using a patient’s own 506 
cancer organoids represents an ambitious goal for personalised medicine, and this approach 507 
is currently not achievable and is too expensive for most healthcare systems. However, 508 
organoid biobanks could represent a realistic intermediate step towards this goal. A gastric 509 
organoid biobank has been established and comprises 64 normal, dysplastic, cancer and 510 
lymph node metastasis organoids from 34 patients.108 This biobank includes most gastric 511 
cancer subtypes, and whole-exome and transcriptome analysis data are available for these 512 
cultures. Analysis has uncovered new understanding of cancer biology and disease 513 
pathogenesis. In addition, the utility of this organoid biobank is reflected in results of the 514 
drug sensitivity screen as this highlights the potential impact of drugs at a very early stage of 515 
development. A breast cancer organoid biobank of >100 primary and metastatic cancers,38 a 516 
lung cancer biobank60 and an ovarian cancer biobank of 56 organoids109 have generated 517 
similar results when used for in vitro drug screening. Across these studies, the organoid 518 
tumour biobanks remarkably maintain disease-specific subtype characteristics such as 519 
morphology, transcriptomic profile and genomic mutational analysis to the native tumour 520 
even after long-term culture.38,60,108,109 Accordingly, they offer an exciting and realistic tool 521 
for precision medicine for use after the identification of a patient’s cancer subtype through 522 
histopathological identification with validated tumour biomarkers. 523 
 524 
Organoid cultures as novel treatment strategies  525 
The immune response to tumours differs according to the biology of the underlying 526 
cancer. Autologous co-culture of tumour organoids derived from patients with colorectal 527 
cancer or non-small cell lung cancer with peripheral lymphocytes leads to the expansion and 528 
enrichment of tumour-reactive T cells.110 These T cells are able to recognise and kill 529 
autologous tumour organoids but, remarkably, ignore healthy autologous organoids. This 530 
method enables us to investigate the mechanisms that underlie patient responses to 531 
immunotherapy. Furthermore, this approach could facilitate the generation of T-cell 532 
populations that could be used for autologous T-cell transfer therapy.  533 
 More direct potential therapeutic applications of organoids exist. Schwartz and 534 
colleagues have demonstrated that airbrush spraying of intestinal organoids onto a 535 
decellularised native extracellular matrix leads to the formation of an epithelial monolayer 536 
that resembles the intestinal surface.111 This is an exciting but underdeveloped concept that 537 
could have therapeutic benefits — for example, to help re-epithelialise areas affected by 538 
radiotherapy.  539 
 Radical surgery for breast cancer is often accompanied by radiotherapy or lymph 540 
node dissection. These adjuvant or neoadjuvant therapies are lifesaving but increase the 541 
risk of life-long complications such as lymphoedema. In 2019, Lenti et al. investigated the 542 
transplantation of lympho-organoids into the region of dissected lymph nodes in mice.112 543 
The lympho-organoids became fully integrated into the endogenous lymphatic system and 544 
restored lymphatic drainage. Furthermore, upon immunisation the lympho-organoids were 545 
able to support antigen-specific endogenous immune responses. Therefore, therapeutic 546 
injection of lympho-organoids could become a novel therapeutic strategy for patients 547 
following radiotherapy or lymph node dissection for breast cancer. 548 
 549 
Conclusions 550 
Tumour-derived organoids are emerging as a tissue culture model that has exciting 551 
translational potential in the era of precision medicine. Tumour-derived organoids 552 
accurately represent the diverse genetic, molecular, morphological, architectural and 553 
functional pathophysiological hallmarks of cancer. Established cultures demonstrate intra-554 
tumour and inter-patient heterogenicity, and can be further modified by genome editing, 555 
co-culture and orthotopic transplantation into rodents. In the clinic, tumour-derived 556 
organoids could be used to inform decisions on cancer treatment. In the wider setting, 557 
however, the translational impact of organoids is dependent on infrastructure, appropriate 558 
skill set and funding and, whilst the use of organoids is limited for now, there is future 559 
potential for this methodology and application to translate into clinical practice (Figure 5). 560 
Overall, this cutting-edge method continues to evolve to provide new insight into the 561 
pathogenesis and evolution of cancer, offering the opportunity to develop new treatment 562 
strategies and enhance the impact of cancer research.  563 
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  889 
Figure 1. Establishing patient-derived organoid cultures. 890 
Patient-derived organoids reflect the genotype and phenotype of the original tissue, with 891 
preserved cellular heterogeneity and structural architecture. The critical steps involved in 892 
establishing a colonic organoid culture are (A) Fresh colonic mucosa is obtained from human 893 
specimens (e.g. by biopsy or surgical resection), (B) Colonic Lgr5+ stem cell-containing crypts 894 
are isolated and embedded in a basement membrane matrix, such as Matrigel, (C) Colonic 895 
organoids are cultured in conditioned media containing specific growth factors and grow 896 
with a central lumen and representative apicobasal polarity. Images from Laboratory of Dr 897 
McLean, University of Aberdeen.  898 
 899 
Figure 2. Advantages and disadvantages of model systems currently used in cancer 900 
research. 901 
There are several model systems used to study cancer in the laboratory. Using human 902 
tumours, the most common models are 2D cell lines, organ-on-a-chip technology, spheroid 903 
cultures, organoid cultures and rodent xenografts, where human tumour is implanted into 904 
live animals. The advantages and disadvantages of these models are outlined here.  905 
  906 
Figure 3. The use of patient-derived tumour organoids in cancer research.  907 
Tumour organoids can be manipulated to improve their functional utility for cancer 908 
research. They can be (A) genetically edited, for example through CRISPR-Cas9 technology, 909 
(B) co-cultured with other cell types such as immune cells, endothelial cells and stromal cells 910 
and (C) microinjected with microbes, antigens or chemicals. Several experimental 911 
approaches can be used to reveal novel insight into cancer pathophysiology such as (D) 912 
immunohistochemistry (E) transwell and other 2D culture-based experiments (F) 913 
immunofluorescence, (G) organoid-on-a-chip technology and (H) xenografts. 914 
 915 
Figure 4. Organoid-derived 2D monolayer cultures can improve the versatility of organoids 916 
for cancer research.  917 
(A) Organoids can be grown in monolayer culture. (B) Transwell cell culture systems further 918 
improve the versatility of this model by allowing access to apical (luminal) and basal 919 
surfaces. (C) Transwell experiments are effective at exploring how luminal antigens or 920 
cytokines impact epithelial barrier integrity in cancer (i.e. through movement of fluorescein 921 
isothiocyanate-dextran or changes in transepithelial electrical resistance). Co-culture 922 
transwell experiments may further improve this model for cancer research (i.e. by 923 
investigating the response of T-cells and dendritic cells to increased barrier permeability 924 
induced by luminal antigens/cytokines in cancer). (D) Using organoid derived 2D monolayers 925 
allows more complex bioimage analysis to be performed. 926 
 927 
Figure 5. Bench to bedside: patient-derived tumour organoids could facilitate personalised 928 
medicine.  929 
Organoids can help direct personalised medicine through (A) using immunohistochemical 930 
markers to subtype cancers and predicting tumour response to specific therapies via 931 
biobank data, (B) by predicting an individual’s response to a specific therapy by organoid 932 
culture using tumour-derived organoids, (C) Future applications of organoids may involve a 933 
more direct role in treatment, such as using organoids to generate autologous tumour-934 
reactive T cells.  935 





